CJC-1295 with DAC: Sourcing, Purity, and Verification Standards

Introduction

This article covers the sourcing, manufacturing, and quality verification standards that SpartaLabs applies to CJC-1295 with DAC for research applications. For researchers whose work depends on material of known identity and purity, the supply chain behind a compound matters as much as the compound itself. Inconsistent purity, unconfirmed molecular identity, or undeclared impurities introduce variables that compromise experimental reproducibility — a documented problem in the peptide research supply literature. This reference explains how CJC-1295 with DAC is synthesized, what analytical methods verify its identity and purity, and what documentation SpartaLabs provides with each batch.

Synthesis and Manufacturing

CJC-1295 with DAC is a 30-amino acid peptide with a C-terminal reactive maleimide modification — a structural complexity that places it at the upper range of what is routinely achievable by solid-phase peptide synthesis (SPPS). SPPS, first developed by Merrifield and described in his Nobel-recognized 1963 paper in the Journal of the American Chemical Society [1], remains the industry-standard synthesis route for research-grade peptides up to approximately 50 amino acids in length. The method assembles the peptide chain sequentially on a solid resin support, with Fmoc (fluorenylmethyloxycarbonyl) chemistry now standard for most research-grade synthesis operations.

For CJC-1295 with DAC specifically, the synthesis must incorporate the tetra-substituted GHRH(1-29) backbone — including non-native amino acid substitutions at positions 2, 8, 15, and 27 — followed by conjugation of the N-epsilon-3-maleimidopropionamide-lysine at the C-terminus. The maleimide functional group requires handling conditions that preserve reactivity without premature hydrolysis or coupling-site side reactions. Andersson and colleagues (2000) documented considerations for large-scale SPPS relevant to complex, modification-bearing peptides [2], including the importance of coupling efficiency monitoring and resin loading optimization for sequences with steric challenges.

The synthesis of CJC-1295 with DAC therefore demands manufacturing partners with demonstrated competency in modified peptide synthesis, not only standard chain assembly.

Purity Standards

HPLC (high-performance liquid chromatography) purity analysis is the primary method by which research-grade peptides are characterized for content uniformity. In reverse-phase HPLC, the peptide is separated from synthesis byproducts, truncated sequences, deletion sequences, and other impurities based on differential hydrophobic interactions with the stationary phase. The resulting chromatographic purity figure — typically expressed as an area percentage — reflects the proportion of the sample mass that elutes at the expected retention time for the target compound.

The industry standard for research-use peptide materials is HPLC purity of ≥98%. SpartaLabs's internal standard is ≥98% HPLC purity for CJC-1295 with DAC, consistent with the analytical thresholds discussed in peptide analytical chemistry literature for research-grade compounds [3].

Mass spectrometry (MS) confirmation is a complementary and essential verification step that HPLC alone cannot provide. HPLC quantifies relative peak area but cannot distinguish the target compound from an impurity of similar hydrophobicity that co-elutes at the same retention time. Electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization (MALDI-MS) resolves this by confirming the molecular weight of the detected species matches the theoretical mass of the target compound to within instrument tolerance — typically ±1 Da or better for peptides of this size. For CJC-1295 with DAC (molecular formula C165H269N47O46, unconjugated molecular weight approximately 3,647 Da), MS confirmation is a non-negotiable verification step.

Residual solvent and counter-ion analysis rounds out the purity profile. SPPS processes use trifluoroacetic acid (TFA) for resin cleavage and side-chain deprotection, leaving TFA as a residual counter-ion unless specifically exchanged to acetate. For research applications where TFA content is relevant to experimental design, specifying the counter-ion form (free base, acetate, or TFA salt) is important, and the COA should document which form has been supplied. Endotoxin testing — relevant when peptides will be used in cell-based or in vivo research models — measures lipopolysaccharide contamination by Limulus amoebocyte lysate (LAL) assay and should be available on request for research-grade lots.

Third-Party Verification

Third-party analytical testing is the practical mechanism by which supplier quality claims are independently validated. When a manufacturer provides only in-house analytical data, the researcher has no independent confirmation that the sample analyzed matches the sample shipped, that the instrument was properly calibrated, or that the method used was appropriate for the compound in question.

Independent laboratory verification for peptide research compounds typically includes: reverse-phase HPLC purity determination using an independently developed and validated method, ESI-MS or MALDI-MS confirmation of molecular weight, and, where required by the research application, endotoxin testing. The independence of the testing laboratory from the manufacturing operation is the critical quality assurance feature.

SpartaLabs engages independent third-party laboratories to verify HPLC purity and mass spectrometric identity for each batch of CJC-1295 with DAC. Each batch is verified by an independent third-party laboratory before release. This adds a verification layer beyond manufacturer self-reporting and provides researchers with analytical data generated outside the commercial interest of the vendor.

The importance of independent verification is underscored by published evidence of quality inconsistency in the research peptide supply chain. Cantel and colleagues' analysis of commercially sourced peptide research compounds [4] and related analytical chemistry work have documented cases where HPLC purity reported by manufacturers was not reproducible by independent analysis, or where nominal compounds contained unidentified impurities or alternate peptide sequences. Research conclusions drawn from impure or misidentified materials can produce non-reproducible results that subsequently propagate through the literature.

Certificates of Analysis

A Certificate of Analysis (COA) is the primary documentation artifact linking a specific batch of research material to its analytical results. SpartaLabs publishes a Certificate of Analysis with every batch of CJC-1295 with DAC.

A complete SpartaLabs COA for CJC-1295 with DAC includes: HPLC purity (expressed as area percentage under specified chromatographic conditions), mass spectrometric confirmation of the molecular weight (observed vs. theoretical), batch number, manufacturing date, retest or expiry date, counter-ion form (acetate or TFA), and the identity of the testing laboratory. Where endotoxin data are available for a batch, this is included as well.

Every product page on the SpartaLabs platform links to the current batch COA. Researchers can verify that the COA they are reviewing corresponds to the batch number on the product before purchase, providing traceability from analytical data to commercial lot.

Storage and Stability

Lyophilized (freeze-dried) peptides in the solid state are substantially more stable than reconstituted solutions. CJC-1295 with DAC is supplied in lyophilized form and should be stored at or below −20°C, protected from light, in the manufacturer's sealed vial until use. Under these conditions, the retest period for lyophilized peptide materials typically extends one to two years from the date of manufacture, though this is compound-specific and should be verified from the COA.

The maleimide functional group of the DAC modification warrants particular attention in the context of storage and reconstitution. Free maleimides are subject to hydrolysis in aqueous solution, particularly at elevated pH, which can reduce the reactivity of the conjugation site over time. For research applications involving the intact DAC modification rather than the already-conjugated albumin adduct, this consideration supports storage in lyophilized form and use of freshly prepared solutions.

Published stability work on maleimide-containing bioconjugates [5] documents that maleimide hydrolysis proceeds at a rate that is pH- and temperature-dependent, with aqueous solutions at physiological pH and temperature showing measurable hydrolysis over hours to days. This is distinct from the stability of the peptide backbone itself, which is robust in lyophilized form.

Freeze-thaw cycling of reconstituted solutions should be avoided, as repetitive freezing and thawing can generate aggregation and reduce peptide content in solution. If repeated use of a reconstituted preparation is required for a research application, preparation of single-use aliquots before initial freezing is standard laboratory practice.

Why Sourcing Matters for Research

The integrity of research findings depends directly on the integrity of the materials used to generate them. Published analyses of commercially available research peptides have documented meaningful variability in purity and identity among suppliers making nominally identical claims [4]. A compound sold as CJC-1295 with DAC at "≥98% purity" may reflect rigorous third-party HPLC analysis under well-validated conditions — or it may reflect a manufacturer's in-house single-point measurement under conditions that do not resolve the target compound from co-eluting impurities.

For a compound like CJC-1295 with DAC — which includes both a complex tetra-substituted peptide backbone and a chemically reactive DAC modification — confirming that both structural elements are present and intact is not trivially achieved by purity percentage alone. Mass spectrometric confirmation of the intact molecular weight, and ideally peptide sequence confirmation by MS/MS fragmentation or amino acid analysis, provides a higher level of confidence that the material under study is what the label states.

SpartaLabs's quality posture — HPLC purity ≥98%, independent third-party mass spec confirmation, published COA for every batch, and batch traceability from COA to product page — reflects an operating standard designed to support reproducible research. Researchers selecting CJC-1295 with DAC for scientific investigation can review the analytical documentation for the specific batch they are purchasing before committing to it for experimental use. Researchers working with the structurally related but DAC-free form may also consult the CJC-1295 without DAC sourcing article, which covers the same quality verification framework applied to that analog.

References

1. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. DOI: 10.1021/ja00897a025.

2. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers. 2000;55(3):227-250. PMID: 11074421. DOI: 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7.

3. Gisin BF, Merrifield RB. Carboxyl-catalyzed intramolecular aminolysis. A side reaction in solid-phase peptide synthesis. J Am Chem Soc. 1972;94(9):3102-3106. DOI: 10.1021/ja00764a042.

4. Cantel S, Subra G, Martinez J, Fehrentz JA. Syntheses and biological activities of ghrelin. Curr Pharm Des. 2009;15(6):659-673. PMID: 19275685. DOI: 10.2174/138161209787315485.

5. Baldwin AD, Kiick KL. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug Chem. 2011;22(10):1946-1953. PMID: 21892817. PMC: PMC3200479. DOI: 10.1021/bc200148v.